Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001687880 XXXXXXXX LIVE 6 Common Stock, par value $0.001 per share 08/11/2025 false 0001544227 87978U108 Tempest Therapeutics, Inc. 2000 Sierra Point Parkway Suite 400 Brisbane CA 94005 Max Eisenberg 415-801-8100 One Sansome Street Suite 1650 San Francisco CA 94104 0001687880 N Versant Venture Capital VI, L.P. b WC N DE 16149 0 16149 0 16149 N 0.4 PN Comment to Row 2: This Schedule 13D is filed by Versant Venture Capital IV, L.P. ("Versant IV"), Versant Side Fund IV, L.P. ("Side Fund IV"), Versant Ventures IV, LLC ("LLC IV"), Versant Venture Capital VI, L.P. ("Versant VI"), Versant Ventures VI GP, L.P. ("GP VI"), Versant Ventures VI GP-GP, LLC ("LLC VI"), Versant Vantage II, L.P. ("Vantage II LP"), Versant Vantage II GP, L.P. ("Vantage II GP"), Versant Vantage II GP-GP, LLC ("Vantage II LLC" and, with Versant IV, Side Fund IV, LLC IV, Versant VI, GP VI, LLC VI, Vantage II LP and Vantage II GP, collectively, the "Reporting Persons"). LLC IV is the general partner of Versant IV and Side Fund IV, and LLC IV has voting, investment and dispositive power over the shares held by each of Versant IV and Side Fund IV. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Each of Vantage II LLC and Vantage II GP share voting, investment and dispositive power over the shares held by Vantage II LP. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 4,440,161 shares of Common Stock (as defined in Item 1 of the Original Schedule 13D (as defined in Item 1 below)) outstanding as of August 4, 2025, as set forth in the Issuer's quarterly report on Form 10-Q for the quarter ended June 30, 2025, filed with the United States Securities and Exchange Commission (the "Commission") on August 11, 2025 (the "Form 10-Q"). 0001777654 N Versant Ventures VI GP, L.P. b AF N DE 0 16149 0 16149 16149 N 0.4 PN Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 4,440,161 shares of Common Stock outstanding as of August 4, 2025, as set forth in the Form 10-Q. 0001777652 N Versant Ventures VI GP-GP, LLC b AF N DE 0 16149 0 16149 16149 N 0.4 OO Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Versant VI. LLC VI is the general partner of GP VI, which is the general partner of Versant VI. Each of LLC VI and GP VI share voting, investment and dispositive power over the shares held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 4,440,161 shares of Common Stock outstanding as of August 4, 2025, as set forth in the Form 10-Q. 0001832235 N Versant Vantage II, L.P. b WC N DE 162972 0 162972 0 162972 N 3.7 PN Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Vantage II LP. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Each of Vantage II LLC and Vantage II GP share voting, investment and dispositive power over the shares held by Vantage II LP and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 4,440,161 shares of Common Stock outstanding as of August 4, 2025, as set forth in the Form 10-Q. 0001839790 N Versant Vantage II GP, L.P. b AF N DE 0 162972 0 162972 162972 N 3.7 PN Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Vantage II LP. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Each of Vantage II LLC and Vantage II GP share voting, investment and dispositive power over the shares held by Vantage II LP and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 4,440,161 shares of Common Stock outstanding as of August 4, 2025, as set forth in the Form 10-Q. 0001839789 N Versant Vantage II GP-GP, LLC b AF N DE 0 162972 0 162972 162972 N 3.7 OO Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Vantage II LP. Vantage II LLC is the general partner of Vantage II GP, which is the general partner of Vantage II LP. Each of Vantage II LLC and Vantage II GP share voting, investment and dispositive power over the shares held by Vantage II LP and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 based on 4,440,161 shares of Common Stock outstanding as of August 4, 2025, as set forth in the Form 10-Q. 0001456590 N Versant Venture Capital IV, L.P. b WC N DE 90084 0 90084 0 90084 N 2.0 PN Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Versant IV. LLC IV is the general partner of Versant IV and has voting, investment and dispositive power over the shares held by Versant IV and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 4,440,161 shares of Common Stock outstanding as of August 4, 2025, as set forth in the Form 10-Q. 0001456591 N Versant Side Fund IV, L.P. b WC N DE 567 0 567 0 567 N 0.0 PN Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page are held by Side Fund IV. LLC IV is the general partner of Side Fund IV and has voting, investment and dispositive power over the shares held by Side Fund IV and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 4,440,161 shares of Common Stock outstanding as of August 4, 2025, as set forth in the Form 10-Q. Y Versant Ventures IV, LLC b AF N DE 0 90651 0 90651 90651 N 2.0 OO Comment to Row 2: This Schedule 13D is filed by the Reporting Persons. The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13D. The shares reported on this cover page includes (i) 90,084 shares held by Versant IV; and (ii) 567 shares held by Side Fund IV. LLC IV is the general partner of Versant IV and Side Fund IV, and LLC IV has voting, investment and dispositive power over the shares held by each of Versant IV and Side Fund IV and as a result may be deemed to have beneficial ownership over such securities. The percentage in Row 13 is based on 4,440,161 shares of Common Stock outstanding as of August 4, 2025, as set forth in the Form 10-Q. Common Stock, par value $0.001 per share Tempest Therapeutics, Inc. 2000 Sierra Point Parkway Suite 400 Brisbane CA 94005 This Amendment No. 6 (this "Amendment") amends and supplements the Schedule 13D originally filed by the Reporting Persons with the Commission on May 9, 2022, as amended by Amendment No. 1 filed with the Commission on November 9, 2023, Amendment No. 2 filed with the Commission on February 8, 2024, Amendment No. 3 filed with the Commission on May 13, 2024, Amendment No. 4 filed with the Commission on August 12, 2024 and Amendment No. 5 filed with the Commission on February 11, 2025 ("Amendment No. 5") (collectively, the "Original Schedule 13D"). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged; provided, however, that all references in the Original Schedule 13D to the number of shares of the Issuer's Common Stock held by each Reporting Person and the number of shares of the Issuer's Common Stock outstanding on each such Reporting Person's cover page to this Amendment are updated to reflect a one-for-thirteen (1:13) reverse stock split of the Issuer's outstanding Common Stock that was effective as of April 8, 2025. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D. This Amendment is being filed to update the aggregate percentage of Common Stock owned by the Reporting Persons due to dilution caused by the Issuer's sales of additional shares of its Common Stock from time to time since the date of the filing of Amendment No. 5. Such transactions resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in Amendment No. 5. See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments. See Items 7-11 and 13 of the cover pages of this Amendment for each Reporting Person and the corresponding comments. Versant Venture Capital VI, L.P. /s/Max Eisenberg Max Eisenberg/COO of Versant Ventures VI GP-GP, LLC, the general partner of Versant Ventures VI GP, L.P., the GP of Versant Venture Capital VI, L.P. 08/13/2025 Versant Ventures VI GP, L.P. /s/Max Eisenberg Max Eisenberg/Chief Operating Officer of Versant Ventures VI GP-GP, LLC, the general partner of Versant Ventures VI GP, L.P. 08/13/2025 Versant Ventures VI GP-GP, LLC /s/Max Eisenberg Max Eisenberg/Chief Operating Officer 08/13/2025 Versant Vantage II, L.P. /s/Max Eisenberg Max Eisenberg/COO of Versant Vantage II GP-GP, LLC, the general partner of Versant Vantage II GP, L.P., the GP of Versant Vantage II, L.P. 08/13/2025 Versant Vantage II GP, L.P. /s/Max Eisenberg Max Eisenberg/Chief Operating Officer of Versant Vantage II GP-GP, LLC, the general partner of Versant Vantage II GP, L.P. 08/13/2025 Versant Vantage II GP-GP, LLC /s/Max Eisenberg Max Eisenberg/Chief Operating Officer 08/13/2025 Versant Venture Capital IV, L.P. /s/Max Eisenberg Max Eisenberg/Chief Operating Officer of Versant Ventures IV, LLC, the general partner of Versant Venture Capital IV, L.P. 08/13/2025 Versant Side Fund IV, L.P. /s/Max Eisenberg Max Eisenberg/Chief Operating Officer of Versant Ventures IV, LLC, the general partner of Versant Side Fund IV, L.P. 08/13/2025 Versant Ventures IV, LLC /s/Max Eisenberg Max Eisenberg/Chief Operating Officer 08/13/2025